Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 193

1.

Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.

Nganou-Makamdop K, Billingsley JM, Yaffe Z, O'Connor G, Tharp GK, Ransier A, Laboune F, Matus-Nicodemos R, Lerner A, Gharu L, Robertson JM, Ford ML, Schlapschy M, Kuhn N, Lensch A, Lifson J, Nason M, Skerra A, Schreiber G, Bosinger SE, Douek DC.

PLoS Pathog. 2018 Aug 24;14(8):e1007246. doi: 10.1371/journal.ppat.1007246. eCollection 2018 Aug.

2.

A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery.

Hoffmann K, Milech N, Juraja SM, Cunningham PT, Stone SR, Francis RW, Anastasas M, Hall CM, Heinrich T, Bogdawa HM, Winslow S, Scobie MN, Dewhurst RE, Florez L, Ong F, Kerfoot M, Champain D, Adams AM, Fletcher S, Viola HM, Hool LC, Connor T, Longville BAC, Tan YF, Kroeger K, Morath V, Weiss GA, Skerra A, Hopkins RM, Watt PM.

Sci Rep. 2018 Aug 22;8(1):12538. doi: 10.1038/s41598-018-30790-2.

3.

Reprogramming human siderocalin to neutralize petrobactin, the essential iron scavenger of Anthrax bacillus.

Dauner M, Eichinger A, Lücking G, Scherer S, Skerra A.

Angew Chem Int Ed Engl. 2018 Jul 31. doi: 10.1002/anie.201807442. [Epub ahead of print]

PMID:
30063283
4.

Anticalin® Proteins as Therapeutic Agents in Human Diseases.

Rothe C, Skerra A.

BioDrugs. 2018 Jun;32(3):233-243. doi: 10.1007/s40259-018-0278-1. Review.

5.

Structural Basis for the Specific Cotranslational Incorporation of p-Boronophenylalanine into Biosynthetic Proteins.

Schiefner A, Nästle L, Landgraf M, Reichert AJ, Skerra A.

Biochemistry. 2018 May 8;57(18):2597-2600. doi: 10.1021/acs.biochem.8b00171. Epub 2018 Apr 24.

PMID:
29668275
6.

Anticalins Reveal High Plasticity in the Mode of Complex Formation with a Common Tumor Antigen.

Schiefner A, Gebauer M, Richter A, Skerra A.

Structure. 2018 Apr 3;26(4):649-656.e3. doi: 10.1016/j.str.2018.02.003. Epub 2018 Mar 8.

PMID:
29526433
7.

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.

Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M.

Sci Rep. 2018 Feb 16;8(1):3212. doi: 10.1038/s41598-018-20811-5.

8.

Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models.

Friedrich L, Kornberger P, Mendler CT, Multhoff G, Schwaiger M, Skerra A.

Biol Chem. 2018 Feb 23;399(3):235-252. doi: 10.1515/hsz-2017-0207.

PMID:
29140786
9.

Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.

Gebauer M, Skerra A.

Bioorg Med Chem. 2018 Jun 1;26(10):2882-2887. doi: 10.1016/j.bmc.2017.09.016. Epub 2017 Sep 15.

PMID:
29102080
10.

The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.

Breibeck J, Skerra A.

Biopolymers. 2018 Jan;109(1). doi: 10.1002/bip.23069. Epub 2017 Oct 27.

11.

Rational Design of an Anticalin-Type Sugar-Binding Protein Using a Genetically Encoded Boronate Side Chain.

Edwardraja S, Eichinger A, Theobald I, Sommer CA, Reichert AJ, Skerra A.

ACS Synth Biol. 2017 Dec 15;6(12):2241-2247. doi: 10.1021/acssynbio.7b00199. Epub 2017 Oct 18.

PMID:
28937743
12.

Tight Molecular Recognition of Benzo[a]pyrene by a High-Affinity Antibody.

Eichinger A, Neumaier I, Pschenitza M, Niessner R, Knopp D, Skerra A.

Angew Chem Int Ed Engl. 2017 Aug 21;56(35):10592-10597. doi: 10.1002/anie.201703893. Epub 2017 Jul 21.

PMID:
28603847
13.

Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.

Nováková Z, Foss CA, Copeland BT, Morath V, Baranová P, Havlínová B, Skerra A, Pomper MG, Barinka C.

Prostate. 2017 May;77(7):749-764. doi: 10.1002/pros.23311. Epub 2017 Mar 1.

PMID:
28247415
14.

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ.

Blood. 2017 Feb 23;129(8):970-980. doi: 10.1182/blood-2016-08-732800. Epub 2016 Dec 27.

15.

Aligning, analyzing, and visualizing sequences for antibody engineering: Automated recognition of immunoglobulin variable region features.

Jarasch A, Skerra A.

Proteins. 2017 Jan;85(1):65-71. doi: 10.1002/prot.25193. Epub 2016 Nov 20.

PMID:
27770557
16.

PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.

Kuhn N, Schmidt CQ, Schlapschy M, Skerra A.

Bioconjug Chem. 2016 Oct 19;27(10):2359-2371. Epub 2016 Sep 26.

PMID:
27598771
17.

Engineering of alanine dehydrogenase from Bacillus subtilis for novel cofactor specificity.

Lerchner A, Jarasch A, Skerra A.

Biotechnol Appl Biochem. 2016 Sep;63(5):616-624. doi: 10.1002/bab.1414. Epub 2015 Sep 11.

PMID:
26202482
18.

Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity.

Chhabra KH, Adams JM, Jones GL, Yamashita M, Schlapschy M, Skerra A, Rubinstein M, Low MJ.

Mol Metab. 2016 Aug 5;5(10):869-881. doi: 10.1016/j.molmet.2016.07.012. eCollection 2016 Oct.

19.

Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.

Gande SL, Saxena K, Sreeramulu S, Linhard V, Kudlinzki D, Heinzlmeir S, Reichert AJ, Skerra A, Kuster B, Schwalbe H.

Chembiochem. 2016 Dec 2;17(23):2257-2263. doi: 10.1002/cbic.201600483. Epub 2016 Nov 9.

PMID:
27685543
20.

Comparison of enzymatic properties and small molecule inhibition of γ-glutamyltranspeptidases from pathogenic and commensal bacteria.

Bolz C, Bach NC, Meyer H, Müller G, Dawidowski M, Popowicz G, Sieber SA, Skerra A, Gerhard M.

Biol Chem. 2016 Dec 20. pii: /j/bchm.ahead-of-print/hsz-2016-0198/hsz-2016-0198.xml. doi: 10.1515/hsz-2016-0198. [Epub ahead of print]

PMID:
27636829

Supplemental Content

Loading ...
Support Center